Stock Watch: Johnson & Johnson's Fast And Slow Lanes
What Is Not Said May Be More Important Than What Is
With all the commentary on J&J’s acquisition strategy and its consumer spin-off, the fourth-quarter performance of its pharmaceutical division went almost unnoticed.
